I would be cautious about trying to buy the bottom on ARIA. Even in the $4's it has a market cap of $800+ million. Iclusig is still the go to drug for a specific CML mutation that causes resistance to Gleevec, Dasatinib and Nilotinib, but unless it can expand beyond the current refractory indication, I question whether this indication will ever cover ARIA's considerable expenses. Once a drug gets a regulatory black mark (deserved or not) there is a long term memory attached to it and the market sees it as damaged goods. ARIA would like to take a bite out of Gleevec's multi-billion market share, and the perception of potential success is what fueled the stock's high valuation. The safety issues have now put a damper on those expectations.